Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) have been assigned an average rating of “Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $7.83.
AQST has been the subject of several analyst reports. Leerink Partnrs upgraded Aquestive Therapeutics to a “strong-buy” rating in a research note on Friday, May 10th. SVB Leerink initiated coverage on Aquestive Therapeutics in a research note on Friday, May 10th. They set an “outperform” rating and a $8.00 price target for the company. Piper Sandler initiated coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They set an “overweight” rating and a $10.00 price target for the company. JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, June 26th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research note on Friday, July 26th.
Get Our Latest Analysis on Aquestive Therapeutics
Institutional Inflows and Outflows
Aquestive Therapeutics Trading Down 0.5 %
AQST stock opened at $3.80 on Wednesday. The company has a market capitalization of $345.95 million, a P/E ratio of -9.05 and a beta of 2.81. Aquestive Therapeutics has a twelve month low of $1.25 and a twelve month high of $6.23. The business has a 50 day simple moving average of $2.86 and a 200-day simple moving average of $3.32.
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The firm had revenue of $12.05 million during the quarter, compared to analyst estimates of $12.22 million. During the same period in the prior year, the firm earned $0.11 earnings per share. Research analysts predict that Aquestive Therapeutics will post -0.49 EPS for the current fiscal year.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Featured Stories
- Five stocks we like better than Aquestive Therapeutics
- What Are the FAANG Stocks and Are They Good Investments?
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- What Are Dividend Challengers?
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- What is a Low P/E Ratio and What Does it Tell Investors?
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.